Capital.com
UK retail investors are bullish on equities but worry about the cost-of-living crisis, falling stock prices and geopolitical risks in the year ahead.
LONDON, UK / ACCESSWIRE / January 26, 2024 / Seven in 10 retail (77%) traders and investors in the UK are taking a neutral-to-optimistic view on financial markets in 2024, according to a new nationally representative survey commissioned by online retail trading platform, Capital.com- with 35% of respondents expecting stocks to be the best performing asset class over the next six to 12 months. These findings affirm that market confidence among UK investors remains high, despite wider macro risks.
The findings are based on a nationally representative survey of 19,451 UK adults, of which 2,036 are traders or investors. In this survey, investors and traders are defined as adults who had invested or traded in mutual funds, bonds, forex, commodities, options, CFDs or spread bets in the past 12 months. The survey, commissioned by Capital.com and polled by Find Out Now, was carried out between 21 Nov to 4 Dec 2023.
Commenting on the upbeat investor sentiment revealed by the findings of the survey, Daniela Hathorn, Senior Market Analyst, Capital.com, said:
"Supported by positive economic data at the tail end of 2023, investors are perhaps approaching 2024 with an air of optimism. Yes, there are pockets of weakness in the economy, especially in the UK and the euro area, but global economic growth in 2023 has fared much better than expected. Of course that doesn't mean the same will happen in 2024, but with investors widely expecting interest rates to fall this year, many expect the recent resilience to be carried through as looser financing conditions make up for some of the loss in productivity and growth."
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.The survey further revealed a healthy interest in equity markets, with 35% of respondents expecting stocks to do well in 2024 followed by gold (32%) and oil & gas (31%). Positive market sentiment was further reflected in investors' capital allocation decisions with 30% of respondents saying they would buy or trade stocks in the next six to 12 months -with the majority focusing on growth and tech stocks (52%). Just 9% said they would move their capital into cash over the same period.
According to Daniela, investors' preference for stocks over other asset classes in 2024 is likely the result of improving market conditions.
"Stocks are typically favoured by investors because they are considered the ‘most tangible' of all non-physical investments, which simply means they are easier to measure and understand than other asset classes. Add to that expectations for rate cuts in 2024 and you have the ideal impetus for equity market enthusiasts. With the potential for lower interest rates in 2024, investors are perhaps expecting company valuations to improve making them attractive investments. Tech stocks are renowned for being the market sweethearts as they tend to hold their value even in difficult times, while offering investors greater returns. Similarly, growth stocks can benefit from improved market sentiment and higher valuations."
Cost-of-living crisis results in greater awareness of saving & investing activities
Despite the market optimism, respondents cited the ongoing cost-of-living crisis as the biggest risk to their investment and trading returns with 22% of those surveyed saying they would need to free up investment capital to cover higher expenses.
Consumers have less money to play with, putting pressure on many to amend their trading, savings and investment habits. When asked what they would do with an extra £10,000, the majority of respondents (57%) said they would either put it into a savings account or trade or invest it. Just 10% said they would spend it while 14% said they would overpay their mortgage or put it into a pension plan (6%).
To view this piece of content from www.accesswire.com, please give your consent at the top of this page."The recent period of high inflation has led to a general devaluation of capital unless it was invested in an asset that provided higher returns. It is not surprising that people are more conscious about how they manage their money now that they have seen the cost of living increase exponentially -it is no longer enough to simply save, consumers want to make up for the loss in their purchasing power. This has led to more awareness about investing, leading many to increase their capital allocations to return-generating activities rather than spending," said Daniela.
Other concerns for UK traders and investors in 2024 include falling stock prices (20%) , geopolitical risk (18%) and recession (16%). Tellingly, only 9% said that higher interest rates were of concern to them, suggesting investors expect the UK economy to improve in the year ahead.
"Markets are currently pricing in between five to six 25 bps rate cuts in 2024 from the BoE. Meanwhile, the central bank itself is expecting to make around three rate cuts this year. These misaligned expectations could drive momentum in UK assets over the coming months, especially as upcoming economic data reveals which set of expectations appear to be correct. Nonetheless, rate cuts are expected so investors may be looking to get higher yields on bonds while they can," she added.
END
Notes to Editors
About Capital.com
Capital.com is a high-growth fintech company empowering people to participate in financial markets through simple and innovative online trading platforms. Its intuitive award-winning platform, available on web and app, enables investors to trade thousands of world-renowned markets. To help investors trade with confidence, the platform is fitted with robust risk management controls and transparent pricing while its all-in-one ‘Investmate' app delivers financial lessons and educational content to support clients in their investment journey. Capital.com has a global network with offices located in Cyprus, UK and Australia.
Capital Com (UK) Limited is authorised and regulated by the Financial Conduct Authority (FCA) under registration number 793714. Capital Com SV Investments Limited is Authorised and regulated by the Cyprus Securities and Exchange Commission (CySEC), under licence number 319/17. Capital Com Australia Pty Ltd is authorised and regulated by the Australian Securities and Investments Commission (ASIC) under AFSL Number 513393.
To find out more, please visit: www.capital.com
Disclosures
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money. Professional clients can lose more than they deposit. All trading involves risk. Please refer to our Risk Disclosure Statement.
Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.
The value of shares and ETFs bought through a share dealing account can fall as well as rise, which could mean getting back less than you originally put in. Past performance is no guarantee of future results.
Capital Com (UK) Limited ("CCUK") is registered in England and Wales with company registration number 10506220. CCUK is authorised and regulated by the Financial Conduct Authority ("FCA"), under registration number 793714."
Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
Any information which could be construed as "investment research" has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.
Shamillia Sivathambu
+44 79000 16469
shamillia.sivathambu@capital.com
SOURCE: Capital.com
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI Announces Target to Expand its AI Driven Data Monetization Network to Over 100 Cities Across the Contiguous United States, Starting in the Second Half of 2026 with Corresponding 2027 Revenue Target12.1.2026 14:05:00 CET | Press release
Datavault AI expects to have a fully operational network with over 100 nodes across 33 cities nationwide, generating revenue in the second half of 2026. Target revenue for this project is $400 to $500 million, thereby supporting the $200 million revenue guidance for 2026. With the full deployment of Datavault AI's nodes across 100+ cities throughout the United States, the 2027 revenue target is $2.0 to $3.0 billion for 2027. New York and Philadelphia edge network activation positions Datavault AI to potentially capture a significant share of the insurance and financial sectors, the healthcare industry, and enterprise opportunities. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies, today highlighted the strategic importance of its New York and Philadelphia edge network deployment with Available Infrastructure's SanQtum AI platform. This
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC12.1.2026 13:00:00 CET | Press release
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market. TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreemen
Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access12.1.2026 12:00:00 CET | Press release
SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape Products IKE's patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie's to ensure that underage individuals will not be able to activate or utilize the Company's age-gated products. The IKE Licensing Agreement provides CHUC with a first mover advantage in youth access prevention (one of the FDA's top priorities) and a three-year exclusivity period for age-gated nicotine analogue products. Charlie's will test market the IKE age-gating system this spring with the Company's popular SBX nicotine analogue product line; simultaneously, Charlie's intends to incorporate the revolutionary technology into its PACHA branded Electronic Nicotine Delivery Systems (ENDS). COSTA MESA, CA / ACCESS Newswire / January 12, 2026 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium vapor products space, today reported that the Compan
Datavault AI Celebrates Successful Completion of Dream Bowl XIV, Pioneering Blockchain Innovation in Sports Entertainment12.1.2026 12:00:00 CET | Press release
On January 10, 2026, a few dozen of NFL Alumni Greats (click here for a list of participating athletes) live-autographed 100 Footballs (click here to view the autographed NFL Alumni Footballs) and 500 Jerseys (click here to view the autographed NFL Alumni Jerseys); Starting on February 1, 2026, these special, one-time, live-autographed memorabilia items are to be given away by lottery to eligible holders of Dream Bowl Meme Coin I tokens and, following their distribution date (currently set for February 21, 2026), Dream Bowl Meme Coin II tokens and will be tradable on the upcoming International NIL Exchange; $25,000 E-Sports Scholarships Raised by Sponsors were Given to Dream Bowl Madden and Team E-Sports Champions; and 70 Student Star Athletes Showcased their Talent to USFL, NFL and European League Scouts (click here to view the Special Dream Bowl XIV Participants' Jerseys). PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference9.1.2026 18:35:00 CET | Press release
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level). About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 T
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
